Manuel

Interview Transcript "I was diagnosed with psoriasis about seven years ago.

I like sports overall, but particularly soccer, and as a former goalkeeper, I used my hands a lot. Psoriasis affected it quite a bit. But with Raptiva® (efalizumab), now I can get back to playing and coaching like I used to before.

I tried all kinds of treatments, but none seemed to work until my dermatologist mentioned Raptiva to me. At first I was a little nervous about the Raptiva shot, being scared of needles and all, but after the first one, it was a piece of cake.

Since using Raptiva, the psoriasis in my hands and my feet has improved dramatically. I would say about 97 percent of my psoriasis is gone. It allows me now to be able to touch my family, shake hands at work and grab hold of my son."

Product Indication Raptiva is a medicine given by injection and is used to treat adult patients (18 years or older) with moderate to severe plaque psoriasis who can be treated with medicines that affect the whole body (systemic therapy) or with phototherapy.

Important Safety Information
Raptiva is an immunosuppressive agent and has the potential to increase the risk of infection and reactivate latent, chronic infections. The most serious adverse reactions observed during treatment with Raptiva are serious infections including PML, malignancies, thrombocytopenia, hemolytic anemia, psoriasis worsening and variants, and neurologic events. Some infections were fatal. New infections developing during Raptiva treatment should be monitored closely. Raptiva likely increases the risk for PML. Based on the clinical characteristics of reported cases of PML in Raptiva patients, prolonged exposure to Raptiva and older age may further increase this risk. Patients should be instructed to report any new neurological signs or symptoms to their physician. Physicians treating patients with Raptiva should consider PML in any patient with new-onset neurologic manifestations.

Patients on treatment with Raptiva should not receive live (including live-attenuated) vaccines. Raptiva should not be prescribed in pediatric patients.

The most common adverse reactions associated with Raptiva are a symptom complex that includes headache, chills, fever, nausea, and myalgia within 48 hours following the first 2 injections. In clinical trials, these events were largely mild to moderate when a first dose of 0.7 mg/kg was given. Less than 1% of patients discontinued Raptiva treatment because of these adverse events.

Please see the full Product Information, including Boxed WARNINGS, for additional safety information.

Individual results may vary.